Pharmacokinetic Problems in Peritoneal Drug Administration: Tissue Penetration and Surface Exposure
Open Access
- 2 April 1997
- journal article
- review article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 89 (7) , 480-487
- https://doi.org/10.1093/jnci/89.7.480
Abstract
Both theory and clinical studies demonstrate that drug concentrations in the peritoneal cavity can greatly exceed concentrations in the plasma following intraperitoneal administration. This regional advantage has been associated with clinical activity, including surgically documented complete responses in ovarian cancer patients with persistent or recurrent disease following systemic therapy, and has produced a survival advantage in a recent phase III trial. Two pharmacokinetic problems appear to limit the effectiveness of intraperitoneal therapy: poor tumor penetration by the drug and incomplete irrigation of serosal surfaces by the drug-containing solution. We have examined these problems in the context of a very simple, spatially distributed model. If D is the diffusivity of the drug in a tissue adjacent to the peritoneal cavity and k is the rate constant for removal of the drug from the tissue by capillary blood, the model predicts that (for slowly reacting drugs) the characteristic penetration distance is ( D/k ) 1/2 and the apparent permeability of the surface of a peritoneal structure is ( D/k ) 1/2 . The permeabilityarea product used in classical pharmacokinetic calculations for the peritoneal cavity as a whole is the sum of the products of the tissue-specific permeabilities and the relevant superficial surface areas. Since the model is mechanistic, it provides insight into the expected effect of procedures such as pharmacologic manipulation or physical mixing. We observe that large changes in tissue penetration may be difficult to achieve but that we have very little information on the transport characteristics within tumors in this setting or their response to vasoactive drugs. Enhanced mixing is likely to offer significant potential for improved therapy; however, procedures easily applicable to the clinical setting have not been adequately investigated and should be given high priority. Clinical studies indicate that an increase in irrigated area may be achieved in many patients by individualizing the dialysate volume and consideration of patient position.Keywords
This publication has 30 references indexed in Scilit:
- Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian CancerNew England Journal of Medicine, 1996
- Penetration Kinetics of 2′,3′-Dideoxyinosine in Dermis Is Described by the Distributed ModelPharmaceutical Research, 1995
- Salvage Intraperitoneal Therapy of Ovarian Cancer Employing Cisplatin and Etoposide: A Gynecologic Oncology Group StudyGynecologic Oncology, 1993
- Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin.Journal of Clinical Oncology, 1991
- Peritoneal transport physiologyJournal of the American Society of Nephrology, 1991
- Experimental and clinical status of intraperitoneal chemotherapyEuropean Journal of Cancer and Clinical Oncology, 1990
- Platinum distribution inintraperitoneal tumors afterintraperitoneal cisplatin treatmentCancer Chemotherapy and Pharmacology, 1990
- Chemical modification of tumour blood flowInternational Journal of Hyperthermia, 1988
- Interspecies Scaling of Regional Drug DeliveryJournal of Pharmaceutical Sciences, 1986
- Concentration-Dependent Disappearance of Fluorouracil from Peritoneal Fluid in the Rat: Experimental Observations and Distributed ModelingJournal of Pharmaceutical Sciences, 1982